Novo Nordisk Unveils Oral Wegovy® Achieving 21.6% Weight Loss in Early Responders at ECO 2026
Novo Nordisk
Insulin Developer and Manufacturer
According to the latest subgroup analysis of the OASIS 4 Phase III clinical study, among people receiving oral Wegovy treatment,Approximately 28.8% of subjects achieved at least a 10% weight loss by Week 16 of treatment., defined as "early responders." This groupThe average weight loss at 16 weeks reached 13.2%.，And further increased to 21.6% at the end of the 64-week trial.Meanwhile, even patients who did not meet the "early response" criteria still achieved an average weight loss of 11.5% by the end of the study, demonstrating the consistent efficacy of oral Wegovy across a broader patient population.
In addition to weight loss effects, Novo Nordisk also released significant analysis results regarding the improvement of physical function. Data shows that among patients with evident mobility impairments, 77.3% experienced clinically meaningful improvements in physical function after receiving oral Wegovy treatment, compared to only 42.9% in the placebo group. Relevant assessments covered patients' endurance during activities, ability to stand, ability to bend over, and overall levels of daily activity.
In addition to the OASIS 4 study, Novo Nordisk also announced the analysis results of ORION and OPTIC at ECO2026, further shifting market attention to the competitive landscape in the oral GLP-1 field.
Among them,ORION Indirect Comparison Study Shows Oral Wegovy Superior to Lilly's Oral GLP-1 Candidate Drug Orforglipron 36 mg in Average Weight Loss Effect, while the latter has a risk of discontinuation due to gastrointestinal side effects that is approximately 14 times higher. The OPTIC patient preference study shows that 84% of respondents prefer treatment options similar to oral Wegovy.
Wegovy® Oral Medication Demonstrates Good Safety in Addressing This Complex Disease; Its Safety and Tolerability in the OASIS 4 Trial Are Consistent with the Overall Profile of GLP-1 Receptor Agonists, with the Most Common Adverse Events Being Mild to Moderate Gastrointestinal Reactions That Gradually Diminish Over Time.
Although indirect comparison studies cannot fully replace head-to-head clinical trials, these data remain strategically significant amid the increasingly fierce competition in the GLP-1 market.
Oral GLP-1 products are gradually becoming the focus of competition in the next phase of the industry. Compared with injectables, oral medications have natural advantages in terms of patient acceptance, long-term compliance, grassroots medical promotion, and global market penetration. For the large population that has not yet received GLP-1 treatment, an oral solution is clearly more acceptable. This also means that oral administration is not only a change in dosage form but may also alter the business model and growth logic of the entire obesity treatment market.GLP-1 Track Changes: The Rise of Oral Weight Loss Drugs
Previous Review
A Comprehensive Guide to Antibodies: Structure, Classification, and ADCC/ADCP/CDC Mechanisms
